These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 7998417)

  • 1. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Asanuma H; Tomita T; Komase K; Kawahara K; Danbara H; Hattori N; Watanabe K; Suzuki Y; Nagamine T
    Vaccine; 1994 Sep; 12(12):1083-9. PubMed ID: 7998417
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin.
    Hashigucci K; Ogawa H; Ishidate T; Yamashita R; Kamiya H; Watanabe K; Hattori N; Sato T; Suzuki Y; Nagamine T; Aizawa C; Tamura S; Kurata T; Oya A
    Vaccine; 1996 Feb; 14(2):113-9. PubMed ID: 8852406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen.
    Verweij WR; de Haan L; Holtrop M; Agsteribbe E; Brands R; van Scharrenburg GJ; Wilschut J
    Vaccine; 1998 Dec; 16(20):2069-76. PubMed ID: 9796066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunogenicity of the Escherichia coli heat-labile enterotoxin: role of the A subunit.
    de Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Vaccine; 1996 Mar; 14(4):260-6. PubMed ID: 8744549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of frequent intranasal administration of adjuvant-combined influenza vaccine on the protection against virus infection.
    Tamura S; Yajima A; Hatori E; Tamura S; Asanuma H; Suzuki Y; Aizawa C; Kurata T
    Vaccine; 1997 Nov; 15(16):1784-90. PubMed ID: 9364684
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposal for safety standards for human use of cholera toxin (or Escherichia coli heat-labile enterotoxin) derivatives as an adjuvant of nasal inactivated influenza vaccine.
    Tamura SI; Kurata T
    Jpn J Infect Dis; 2000 Jun; 53(3):98-106. PubMed ID: 10957706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of mutant Escherichia coli heat-labile enterotoxin (LT H44A) as an adjuvant for nasal influenza vaccine.
    Hagiwar Y; Tsuji T; Iwasaki T; Kadowaki S; Asanuma H; Chen Z; Komase K; Suzuki Y; Aizawa C; Kurata T; Tamura S
    Vaccine; 2001 Feb; 19(15-16):2071-9. PubMed ID: 11228379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection.
    Tumpey TM; Renshaw M; Clements JD; Katz JM
    J Virol; 2001 Jun; 75(11):5141-50. PubMed ID: 11333895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy of nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin in healthy volunteers].
    Hashigucci K; Tamura S; Kurata T; Kamiya H; Ishidate T
    Kansenshogaku Zasshi; 1997 Feb; 71(2):153-61. PubMed ID: 9077073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant Escherichia coli heat-labile enterotoxin [LT(R192G)] enhances protective humoral and cellular immune responses to orally administered inactivated influenza vaccine.
    Lu X; Clements JD; Katz JM
    Vaccine; 2002 Jan; 20(7-8):1019-29. PubMed ID: 11803061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers.
    Stephenson I; Zambon MC; Rudin A; Colegate A; Podda A; Bugarini R; Del Giudice G; Minutello A; Bonnington S; Holmgren J; Mills KH; Nicholson KG
    J Virol; 2006 May; 80(10):4962-70. PubMed ID: 16641287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutants of Escherichia coli heat-labile enterotoxin as an adjuvant for nasal influenza vaccine.
    Komase K; Tamura S; Matsuo K; Watanabe K; Hattori N; Odaka A; Suzuki Y; Kurata T; Aizawa C
    Vaccine; 1998; 16(2-3):248-54. PubMed ID: 9607038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mucosal immunogenicity and adjuvant activity of the recombinant A subunit of the Escherichia coli heat-labile enterotoxin.
    De Haan L; Holtrop M; Verweij WR; Agsteribbe E; Wilschut J
    Immunology; 1999 Aug; 97(4):706-13. PubMed ID: 10457227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nasal or intramuscular immunization of mice with influenza subunit antigen and the B subunit of Escherichia coli heat-labile toxin induces IgA- or IgG-mediated protective mucosal immunity.
    Haan L; Verweij WR; Holtrop M; Brands R; van Scharrenburg GJ; Palache AM; Agsteribbe E; Wilschut J
    Vaccine; 2001 Apr; 19(20-22):2898-907. PubMed ID: 11282201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intranasal immunization with live recombinant Lactococcus lactis combined with heat-labile toxin B subunit protects chickens from highly pathogenic avian influenza H5N1 virus.
    Lei H; Peng X; Shu H; Zhao D
    J Med Virol; 2015 Jan; 87(1):39-44. PubMed ID: 24861477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice.
    Barchfeld GL; Hessler AL; Chen M; Pizza M; Rappuoli R; Van Nest GA
    Vaccine; 1999 Feb; 17(7-8):695-704. PubMed ID: 10067675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunization with influenza vaccine and a detoxified mutant of heat labile enterotoxin from Escherichia coli (LTK63).
    Pine S; Barackman J; Ott G; O'Hagan D
    J Control Release; 2002 Dec; 85(1-3):263-70. PubMed ID: 12480330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.